TOP TEN perturbations for 39668_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39668_at
Selected probe(set): 214451_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39668_at (214451_at) across 6674 perturbations tested by GENEVESTIGATOR:
stem cell differentiation study 59 (8d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):8.028277Number of Samples:4 / 4
| Experimental | stem cell differentiation study 59 (8d) |
| WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper. | |
| Control | normal embryonic stem cell sample (WA09) |
| Undifferentiated WA09 embryonic stem cell samples. |
expO breast cancer study 1 (medullary carcinoma, NOS; primary) / expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary)
Relative Expression (log2-ratio):-7.3308225Number of Samples:2 / 2
| Experimental | expO breast cancer study 1 (medullary carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS). | |
| Control | expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary) |
| Primary tumor tissue samples obtained from the breast of patients with intraductal papillary adenocarcinoma with invasion. |
stem cell differentiation study 59 (iDRG; 9d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):7.030656Number of Samples:4 / 4
| Experimental | stem cell differentiation study 59 (iDRG; 9d) |
| Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 1 day. Further details are described in the paper. | |
| Control | normal embryonic stem cell sample (WA09) |
| Undifferentiated WA09 embryonic stem cell samples. |
skin squamous cell carcinoma study 6 / basal cell carcinoma study 2
Relative Expression (log2-ratio):-6.745082Number of Samples:4 / 2
| Experimental | skin squamous cell carcinoma study 6 |
| Primary tumor tissue from the skin of patients with squamous cell carcinoma (SCC). | |
| Control | basal cell carcinoma study 2 |
| Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC). |
expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary) / expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)
Relative Expression (log2-ratio):6.2005415Number of Samples:2 / 2
| Experimental | expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary) |
| Primary tumor tissue samples obtained from the breast of patients with intraductal papillary adenocarcinoma with invasion. | |
| Control | expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary) |
| Primary tumor tissue samples obtained from the breast of patients with adenocarcinoma with squamous metaplasia. |
expO breast cancer study 1 (metaplastic carcinoma, NOS; primary) / expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary)
Relative Expression (log2-ratio):-5.8590717Number of Samples:3 / 2
| Experimental | expO breast cancer study 1 (metaplastic carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with metaplastic carcinoma (NOS). | |
| Control | expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary) |
| Primary tumor tissue samples obtained from the breast of patients with intraductal papillary adenocarcinoma with invasion. |
basal cell carcinoma study 6 (primary) / melanoma study 34 (primary)
Relative Expression (log2-ratio):5.8164406Number of Samples:15 / 14
| Experimental | basal cell carcinoma study 6 (primary) |
| Primary tumor tissue from the skin of patients with primary basal cell carcinoma (BCC). | |
| Control | melanoma study 34 (primary) |
| Primary tumor tissue from the skin of patients with primary cutaneous melanoma (PCM). PCM consisted of 2 thin melanomas (< 1 mm; T1), 3 intermediate-thickness melanomas (1–4 mm; T2-3), and 9 thick melanomas (> 4 mm; T4). |
stem cell differentiation study 59 (iDRG; 12d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):5.5815077Number of Samples:4 / 4
| Experimental | stem cell differentiation study 59 (iDRG; 12d) |
| Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper. | |
| Control | normal embryonic stem cell sample (WA09) |
| Undifferentiated WA09 embryonic stem cell samples. |
breast cancer study 50 (subtype II) / breast cancer study 50 (subtype I)
Relative Expression (log2-ratio):5.0720596Number of Samples:34 / 37
| Experimental | breast cancer study 50 (subtype II) |
| Primary tumor tissue samples obtained from the breast of patients with breast cancer with KFSYSCC subtype II. Samples were collected at the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) between 1991 and 2004. Exclusion criteria: patients with follow-up periods shorter than three years, with the exception of patients who died of the disease within three years of the initial treatment. KFSYSCC subtype II:predominantly negative for ER, variable for PR expression, predominantly positive for HER2, larger tumors dominate (T-stage), propensity to develop distant metastases (47%), increased expressions of cell cycle/proliferation genes, high risk of distant recurrence | |
| Control | breast cancer study 50 (subtype I) |
| Primary tumor tissue samples obtained from the breast of patients with breast cancer with KFSYSCC subtype I. Samples were collected at the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) between 1991 and 2004. Exclusion criteria: patients with follow-up periods shorter than three years, with the exception of patients who died of the disease within three years of the initial treatment. KFSYSCC subtype I:predominantly negative for ER, variable for PR expression, predominantly negative for HER2, in concordance with chemosensitive basal-like intrinsic type, CMF yielded survival outcome similar to those of CAF, increased expressions of cell cycle/proliferation genes, high risk of distant recurrence |
expO breast cancer study 1 (medullary carcinoma, NOS; primary) / expO breast cancer study 1 (cribriform carcinoma; primary)
Relative Expression (log2-ratio):-5.015924Number of Samples:2 / 2
| Experimental | expO breast cancer study 1 (medullary carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS). | |
| Control | expO breast cancer study 1 (cribriform carcinoma; primary) |
| Primary tumor tissue samples obtained from the breast of patients with cribriform carcinoma. |